ACLX

NEUTRALM&A

Arcellx, Inc.

2026-04-10

Price

$114.83

+0.03%

Score13.6Top Tier

Signals7/8 DNA2/13 Act · 0/4 Risk

SentimentNEUTRALScore: 9

Volume0.7xvs 20d avg

Analysis

The core driver behind Arcellx's price action is its pending acquisition by Gilead Sciences for $115 per share in cash plus a $5 Contingent Value Right (CVR). The technical signals (SURGE, ALPHA_MALE, QUIET_STORM) and ultra-low 1.9% realized volatility perfectly reflect a stock that has already repriced and is now pinned in a tight M&A arbitrage holding pattern. Furthermore, the current RISK_ON macro regime and exceptionally tight credit spreads (0.83%) indicate zero systemic financing stress, giving the market supreme confidence that this deal will successfully close in Q2 2026 without regulatory or liquidity hiccups.

Fired Signals

SURGEALPHA MALEQUIET STORMSTEADY CLIMBGOLDEN CROSSBOLLINGER SQUEEZEPERFECT STACKSELLER FATIGUEINSIDE OUT

Key Takeaways

M&A Arbitrage Anchor: ACLX is trading at $114.83, just pennies below Gilead's $115 base cash offer, reflecting near-100% market certainty of deal completion.
CVR Optionality: The remaining upside is tied to a $5 Contingent Value Right contingent on the FDA approval of anito-cel, creating a unique risk/reward dynamic for holdouts.
Macro De-Risking: The RISK_ON environment and normalized yield curve eliminate financing friction, allowing the stock to trade with steady volume and zero distress.

← Back to 2026-04-10 View Full ACLX History →Yahoo Finance &nearr;